Evidence map›Paper›PMID 35403094›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2022

Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction.

Michael X Chen, Nathan Kuehne, Andre Mattman, Jun Liu, Grace Van der Gugten, Bruce Wright

Open access · goldAbstract read
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Michael X ChenDepartment of Laboratory Medicine, Pathology and Medical Genetics, Island Health, Victoria, British Columbia, Canada.
Nathan KuehneDepartment of Laboratory Medicine, Pathology and Medical Genetics, Island Health, Victoria, British Columbia, Canada.
Andre MattmanDepartment of Pathology and Laboratory Medicine, St Paul's Hospital, Vancouver, British Columbia, Canada.
Jun LiuDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Grace Van der GugtenDepartment of Pathology and Laboratory Medicine, St Paul's Hospital, Vancouver, British Columbia, Canada.
Bruce WrightDivision of Medical Sciences, Island Medical Program, University of Victoria, Victoria, British Columbia, Canada.
Island Health · CASt. Paul's Hospital · CAUniversity of British Columbia · CAUniversity of Victoria · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hepcidin is a hormone that regulates systemic iron homeostasis. Serum hepcidin levels are under the influence of various stimuli, particularly inflammation and renal dysfunction. The measurement of hepcidin in circulation is a potentially useful clinical tool in the diagnosis, monitoring and treatment of iron metabolism disorder, although clinical interpretation of hepcidin level remains difficult. We evaluated he diagnostic potential and limitations of hepcidin-25 by investigating its relationship with iron and hematological indices, inflammation, and renal dysfunction. Methods: This retrospective study included 220 adult patients not requiring dialysis. Variations of biologically active hepcidin-25 were examined using a mass spectrometry-based assay in various inflammatory and renal states. The log[hepcidin]:log[ferritin] ratio was calculated as an hepcidin index. Results: In 220 adult patients not requiring dialysis, variation in hepcidin-25 level was significantly larger once CRP exceeded 10 mg/l (p < 0.001). Inflammation was not a determinant of hepcidin-25 in the setting of renal dysfunction. Hepcidin-25 median (7.37 nM) and variance were significantly higher (p < 0.001), once estimated glomerular filtration rate (eGFR) dropped below 30 ml/min/1.73 m Conclusion: Severe renal dysfunction (eGFR < 30) affected hepcidin-25 expression and clearance to variable degree between individuals. Although, hepcidin-25 testing is not warranted in patients with infection, inflammatory autoimmune conditions (CRP > 10 mg/l) and/or severe renal dysfunction (eGFR < 30), the hepcidin index may serve as a potential biomarker for iron deficiency in complex cases.

Indexed as

ACD, anemia of chronic diseaseBiomarkerCBC, complete blood countCKD, chronic kidney diseaseCRP, C-reactive proteinDiagnostic utilityeGFR, estimated glomerular filtration rateHb, hemoglobinHepcidinHPLC/MS/MS, high-performance liquid chromatography tandem mass spectrometryIDA, iron deficiency anemiaID, iron deficiencyIRIDA, iron refractory iron deficiency anemiaIron metabolismLIS, lab information systemMCV, mean corpuscular volume

Identifiers

PMID35403094
PMCPMC8983384
OpenAlexW4220743266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.